Acute-phase serum amyloid A: Perspectives on its physiological and pathological roles

Amyloid

Volumn 19, Issue 1, 2012, Pages 5-14

  Kisilevsky, Robert ^a,b   Manley, Paul N ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

Atherosclerosis; Cholesterol; Cholesterol recycling; Evolution; HDL; Inflammation; Lipopolysaccharide; Pitfalls; Reverse cholesterol transport; Tissue injury

Indexed keywords

ABC TRANSPORTER; ACUTE PHASE PROTEIN; ACUTE PHASE SERUM AMYLOID A; APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PROTEIN ANTIBODY; SERUM AMYLOID A; SERUM AMYLOID A ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AA AMYLOIDOSIS; AMINO TERMINAL SEQUENCE; AMYLOIDOSIS; ATHEROGENESIS; CARBOXY TERMINAL SEQUENCE; CHOLESTEROL METABOLISM; CORONARY ARTERY DISEASE; CYTOKINE RELEASE; DIETARY INTAKE; HUMAN; IN VIVO STUDY; INFLAMMATION; MACROPHAGE; PARACRINE SIGNALING; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REVIEW; SURVIVAL; TISSUE INJURY;

AMINO ACID SEQUENCE; ANIMALS; ATHEROSCLEROSIS; CHOLESTEROL; CONSERVED SEQUENCE; HUMANS; INFLAMMATION; LIPOPOLYSACCHARIDES; LIPOPROTEINS, HDL; MACROPHAGES; MICE; MOLECULAR SEQUENCE DATA; SERUM AMYLOID A PROTEIN;

EID: 84857198063     PISSN: 13506129     EISSN: 17442818     Source Type: Journal    
DOI: 10.3109/13506129.2011.654294     Document Type: Review

References (144)

1. Santiago-Cardona PG, Berrios CA, Ramirez F, Garcia-Arraras JE. Lipopolysaccharides induce intestinal serum amyloid A expression in the sea cucumber Holothuria glaberrima. Dev Comp Immunol 2003;27:105-110. (Pubitemid 36110469)
2. Santiago P, Roig-Lopez JL, Santiago C, Garcia-Arraras. Serum amyloid A protein in an echinoderm: Its primary structure and expression during intestinal regeneration in the sea cucumber Holothuria glaberrima. J Exp Zool 2000;288:335-344. (Pubitemid 32003753)
3. Ancsin JB, Kisilevsky R. The heparin/heparan sulfate-binding site on apo-serum amyloid A. Implications for the therapeutic intervention of amyloidosis. J Biol Chem 1999;274:7172-7181.
4. Kisilevsky R, Tam SP, Ancsin JB. The anti-atherogenic potential of serum amyloid A peptides. Curr Opin Investig Drugs 2008;9:265-273. (Pubitemid 351323379)
5. Fyfe AI, Rothenberg LS, DeBeer FC, Cantor RM, Rotter JI, Lusis AJ. Association between serum amyloid A proteins and coronary Circulation 1997;96:2914-2919.
6. Johnson BD, Kip KE, Marroquin OC, Ridker PM, Kelsey SF, Shaw LJ, Pepine CJ, et al.; National Heart, Lung, and Blood Institute. Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: The National Heart, Lung, and Blood Institute-Sponsored Womens Ischemia Syndrome Evaluation (WISE). Circulation 2004;109:726-732. (Pubitemid 38222891)
7. Erren M, Reinecke H, Junker R, Fobker M, Schulte H, Schurek JO, Kropf J, et al. Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. Arterioscler Thromb Vasc Biol 1999;19:2355-2363. (Pubitemid 29477836)
8. Filep JG, El Kebir D. Serum amyloid A as a marker and mediator of acute coronary syndromes. Future Cardiol 2008;4:495-504.
9. Hua S, Song C, Geczy CL, Freedman SB, Witting PK. A role for acute-phase serum amyloid A and high-density lipoprotein in oxidative stress, endothelial dysfunction and atherosclerosis. Redox Rep 2009;14:187-196.
10. Whicher J, Biasucci L, Rifai N. Inflammation, the acute phase response and atherosclerosis. Clin Chem Lab Med 1999;37:495-503. (Pubitemid 29304412)
11. Whicher J, Rifai N, Biasucci LM. Markers of the acute phase response in cardiovascular disease: An update. Clin Chem Lab Med 2001;39:1054-1064. (Pubitemid 33133625)
12. Malle E, Sodin-Semrl S, Kovacevic A. Serum amyloid A: An acutephase protein involved in tumour pathogenesis. Cell Mol Life Sci 2009;66:9-26.
13. Kisilevsky R, Subrahmanyan L. Serum amyloid A changes high density lipoproteins cellular affinity. A clue to serum amyloid As principal function. Lab Invest 1992;66:778-785.
14. Tam SP, Flexman A, Hulme J, Kisilevsky R. Promoting export of macrophage cholesterol: The physiological role of a major acute-phase protein, serum amyloid A 2.1. J Lipid Res 2002;43:1410-1420.
15. Kisilevsky R, Tam SP. Macrophage cholesterol efflux and the active domains of serum amyloid A 2.1. J Lipid Res 2003;44:2257-2269. (Pubitemid 38082484)
16. Tam SP, Ancsin JB, Tan R, Kisilevsky R. Peptides derived from serum amyloid A prevent, and reverse, aortic lipid lesions in apoE?/- mice. J Lipid Res 2005;46:2091-2101. (Pubitemid 41377461)
17. McGillicuddy FC, de la Llera Moya M, Hinkle CC, Joshi MR, Chiquoine EH, Billheimer JT, Rothblat GH, Reilly MP. Inflammation impairs reverse cholesterol transport in vivo. Circulation 2009;119:1135-1145.
18. Annema W, Nijstad N, T?le M, de Boer JF, Buijs RV, Heeringa P, van der Giet M, Tietge UJ. Myeloperoxidase and serum amyloid A contribute to impaired in vivo reverse cholesterol transport during the acute phase response but not group IIA secretory phospholipase A(2). J Lipid Res 2010;51:743-754.
19. Hosoai H, Webb NR, Glick JM, Tietge UJ, Purdom MS, de Beer FC, Rader DJ. Expression of serum amyloid A protein in the absence of the acute phase response does not reduce HDL cholesterol or apoA-I levels in human apoA-I transgenic mice. J Lipid Res 1999;40:648-653. (Pubitemid 29173767)
20. Coetzee GA, Strachan AF, van der Westhuyzen DR, Hoppe HC, Jeenah MS, de Beer FC. Serum amyloid A-containing human high density lipoprotein 3. Density, size, and apolipoprotein composition. J Biol Chem 1986;261:9644-9651. (Pubitemid 17214087)
21. van der Westhuyzen DR, Coetzee GA, de Beer FC. Serum amyloid A protein in plasma: Characteristics of acute phase HDL. In: Marrink J, van Rijswijk MH (eds). Amyloidosis. Martinus Nijhoff, Dordrecht; 1986, pp. 115-125.
22. Pruzanski W, Stefanski E, de Beer FC, de Beer MC, Ravandi A, Kuksis A. Comparative analysis of lipid composition of normal and acutephase high density lipoproteins. J Lipid Res 2000;41:1035-1047. (Pubitemid 30483006)
23. Jahangiri A, de Beer MC, Noffsinger V, Tannock LR, Ramaiah C, Webb NR, van der Westhuyzen DR, de Beer FC. HDL remodeling during the acute phase response. Arterioscler Thromb Vasc Biol 2009;29:261-267.
24. de Beer MC, Webb NR, Wroblewski JM, Noffsinger VP, Rateri DL, Ji A, van der Westhuyzen DR, de Beer FC. Impact of serum amyloid A on high density lipoprotein composition and levels. J Lipid Res 2010;51:3117-3125.
25. van der Westhuyzen DR, de Beer FC, Webb NR. HDL cholesterol transport during inflammation. Curr Opin Lipidol 2007;18:147-151. (Pubitemid 46412084)
26. Navab M, Reddy ST, Van Lenten BJ, Anantharamaiah GM, Fogelman AM. The role of dysfunctional HDL in atherosclerosis. J Lipid Res 2009;50 Suppl:S145-S149.
27. Khovidhunkit W, Memon RA, Feingold KR, Grunfeld C. Infection and inflammation-induced proatherogenic changes of lipoproteins. J Infect Dis 2000;181 Suppl 3:S462-S472. (Pubitemid 30416122)
28. Tatsuta E, Shirahama T, Sipe JD, Skinner M, Cohen AS. Kinetics of SAP and SAA production by cultured mouse liver cells. Ann N Y Acad Sci 1982;389:467-470. (Pubitemid 12021535)
29. Tatsuta E, Sipe JD, Shirahama T, Skinner M, Cohen AS. Different regulatory mechanisms for serum amyloid A and serum amyloid P synthesis by cultured mouse hepatocytes. J Biol Chem 1983;258:5414-5418. (Pubitemid 13096464)
30. Conti P, Bartle L, Barbacane RC, Reale M, Placido FC, Sipe J. Synergistic activation of serum amyloid A (SAA) by IL-6 and IL-1 in combination on human Hep 3B hepatoma cell line. Role of PGE2 and IL-1 receptor antagonist. Immunol Invest 1995;24:523-535.
31. Ganapathi MK, Rzewnicki D, Samols D, Jiang SL, Kushner I. Effect of combinations of cytokines and hormones on synthesis of serum amyloid A and C-reactive protein in Hep 3B cells. J Immunol 1991;147:1261-1265.
32. Ganapathi MK, May LT, Schultz D, Brabenec A, Weinstein J, Sehgal PB, Kushner I. Role of interleukin-6 in regulating synthesis of C-reactive protein and serum amyloid A in human hepatoma cell lines. Biochem Biophys Res Commun 1988;157:271-277. (Pubitemid 19004856)
33. Jiang SL, Lozanski G, Samols D, Kushner I. Induction of human serum amyloid A in Hep 3B cells by IL-6 and IL-1 β involves both transcriptional and post-transcriptional mechanisms. J Immunol 1995;154:825-831.
34. Mackiewicz A, Speroff T, Ganapathi MK, Kushner I. Effects of cytokine combinations on acute phase protein production in two human hepatoma cell lines. J Immunol 1991;146:3032-3037.
35. Raynes JG, Eagling S, McAdam KP. Acute-phase protein synthesis in human hepatoma cells: Differential regulation of serum amyloid A (SAA) and haptoglobin by interleukin-1 and interleukin-6. Clin Exp Immunol 1991;83:488-491.
36. Rokita H, Loose LD, Bartle LM, Sipe JD. Synergism of interleukin 1 and interleukin 6 induces serum amyloid A production while depressing fibrinogen: A quantitative analysis. J Rheumatol 1994;21:400-405. (Pubitemid 24102821)
37. Kushner I. Regulation of the acute phase response by cytokines. Perspect Biol Med 1993;36:611-622.
38. Kushner I. The phenomenon of the acute phase response. Ann N Y Acad Sci 1982;389:39-48. (Pubitemid 12013176)
39. Sipe JD, Rokita H, de Beer FC. Cytokine regulation of the mouse SAA gene family. In: Mackiewicz A, Kushner I, Baumann H. (eds). Acute Phase Proteins: Molecular Biology, Biochemistry, and Clinical Applications. Boca Raton: CRC Press; 1993, PP. 511-526.
40. Baranova IN, Bocharov AV, Vishnyakova TG, Kurlander R, Chen Z, Fu D, Arias IM, et al. CD36 is a novel serum amyloid A (SAA) receptor mediating SAA binding and SAA-induced signaling in human and rodent cells. J Biol Chem 2010;285:8492-8506.
41. Sandri S, Rodriguez D, Gomes E, Monteiro HP, Russo M, Campa A. Is serum amyloid A an endogenous TLR4 agonist? J Leukoc Biol 2008;83:1174-1180. (Pubitemid 351960349)
42. Su SB, Gong W, Gao JL, Shen W, Murphy PM, Oppenheim JJ, Wang JM. A seven-transmembrane, G protein-coupled receptor, FPRL1, mediates the chemotactic activity of serum amyloid A for human phagocytic cells. J Exp Med 1999;189:395-402. (Pubitemid 29063260)
43. Cai L, de Beer MC, de Beer FC, van der Westhuyzen DR. Serum amyloid A is a ligand for scavenger receptor class B type I and inhibits high density lipoprotein binding and selective lipid uptake. J Biol Chem 2005;280:2954-2961. (Pubitemid 40189405)
44. Cheng N, He R, Tian J, Ye PP, Ye RD. Cutting edge: TLR2 is a functional receptor for acute-phase serum amyloid A. J Immunol 2008;181:22-26.
45. He R, Sang H, Ye RD. Serum amyloid A induces IL-8 secretion through a G protein-coupled receptor, FPRL1/LXA4R. Blood 2003;101:1572-1581. (Pubitemid 36182537)
46. Liang TS, Wang JM, Murphy PM, Gao JL. Serum amyloid A is a chemotactic agonist at FPR2, a low-affinity N-formylpeptide receptor on mouse neutrophils. Biochem Biophys Res Commun 2000;270:331-335. (Pubitemid 30446837)
47. Okamoto H, Katagiri Y, Kiire A, Momohara S, Kamatani N. Serum amyloid A activates nuclear factor-kappaB in rheumatoid synovial fibroblasts through binding to receptor of advanced glycation endproducts. J Rheumatol 2008;35:752-756. (Pubitemid 351747112)
48. Lindhorst E, Young D, Bagshaw W, Hyland M, Kisilevsky R. Acute inflammation, acute phase serum amyloid A and cholesterol metabolism in the mouse. Biochim Biophys Acta 1997;1339:143-154. (Pubitemid 27193322)
49. McAdam KP, Elin RJ, Sipe JD, Wolff SM. Changes in human serum amyloid A and C-reactive protein after etiocholanolone-induced inflammation. J Clin Invest 1978;61:390-394. (Pubitemid 8280409)
50. Patel H, Fellowes R, Coade S, Woo P. Human serum amyloid A has cytokine-like properties. Scand J Immunol 1998;48:410-418. (Pubitemid 28459659)
51. Benditt EP, Eriksen N, Hanson RH. Amyloid protein SAA is an apoprotein of mouse plasma high density lipoprotein. Proc Natl Acad Sci USA 1979;76:4092-4096. (Pubitemid 9249030)
52. Benditt EP, Eriksen N. Amyloid protein SAA is associated with high density lipoprotein from human serum. Proc Natl Acad Sci USA 1977;74:4025-4028. (Pubitemid 8197767)
53. Kinkley SM, Bagshaw WL, Tam SP, Kisilevsky R. The path of murine serum amyloid A through peritoneal macrophages. Amyloid 2006;13:123-134. (Pubitemid 44630055)
54. Sullivan CP, Seidl SE, Rich CB, Raymondjean M, Schreiber BM. Secretory phospholipase A2, group IIA is a novel serum amyloid A target gene: Activation of smooth muscle cell expression by an interleukin-1 receptor-independent mechanism. J Biol Chem 2010;285:565-575.
55. Badolato R, Wang JM, Murphy WJ, Lloyd AR, Michiel DF, Bausserman LL, Kelvin DJ, Oppenheim JJ. Serum amyloid A is a chemoattractant: Induction of migration, adhesion, and tissue infiltration of monocytes and polymorphonuclear leukocytes. J Exp Med 1994;180:203-209. (Pubitemid 24181069)
56. Chen ES, Song Z, Willett MH, Heine S, Yung RC, Liu MC, Groshong SD, et al. Serum amyloid A regulates granulomatous inflammation in sarcoidosis through Toll-like receptor-2. Am J Respir Crit Care Med 2010;181:360-373.
57. Mullan RH, McCormick J, Connolly M, Bresnihan B, Veale DJ, Fearon U. A role for the high-density lipoprotein receptor SR-B1 in synovial inflammation via serum amyloid-A. Am J Pathol 2010;176:1999-2008.
58. Thomas MJ, Bhat S, Sorci-Thomas MG. Three-dimensional models of HDL apoA-I: Implications for its assembly and function. J Lipid Res 2008;49:1875-1883.
59. Huang R, Silva RA, Jerome WG, Kontush A, Chapman MJ, Curtiss LK, Hodges TJ, Davidson WS. Apolipoprotein A-I structural organization in high-density lipoproteins isolated from human plasma. Nat Struct Mol Biol 2011;18:416-422.
60. Li C, Kisilevsky R. Serum amyloid A, in vivo splenic cholesterol export and its potential implications in hemolytic disorders. Amyloid 2008;15:246-254.
61. Banka CL, Yuan T, de Beer MC, Kindy M, Curtiss LK, de Beer FC. Serum amyloid A (SAA): Influence on HDL-mediated cellular cholesterol efflux. J Lipid Res 1995;36:1058-1065.
62. Artl A, Marsche G, Pussinen P, Knipping G, Sattler W, Malle E. Impaired capacity of acute-phase high density lipoprotein particles to deliver cholesteryl ester to the human HUH-7 hepatoma cell line. Int J Biochem Cell Biol 2002;34:370-381. (Pubitemid 34164280)
63. Sipe JD, Vogel SN, Ryan JL, McAdam KP, Rosenstreich DL. Detection of a mediator derived from endotoxin-stimulated macrohpages that induces the acute phase serum amyloid A response in mice. J Exp Med 1979;150:597-606. (Pubitemid 10232138)
64. Vogel SN, Sipe JD. The role of macrophages in the acute phase SAA response to endotoxin. Surv Immunol Res 1982;1:235-241. (Pubitemid 13240221)
65. Ghezzi P, Sipe JD. Dexamethasone modulation of LPS, IL-1, and TNF stimulated serum amyloid A synthesis in mice. Lymphokine Res 1988;7:157-166.
66. Ray A, Hannink M, Ray BK. Concerted participation of NF-kappa B and C/EBP heteromer in lipopolysaccharide induction of serum amyloid A gene expression in liver. J Biol Chem 1995;270:7365-7374.
67. Kitchens RL, Thompson PA, Munford RS, OKeefe GE. Acute inflammation and infection maintain circulating phospholipid levels and enhance lipopolysaccharide binding to plasma lipoproteins. J Lipid Res 2003;44:2339-2348. (Pubitemid 38082492)
68. Kitchens RL, Thompson PA. Impact of sepsis-induced changes in plasma on LPS interactions with monocytes and plasma lipoproteins: Roles of soluble CD14, LBP, and acute phase lipoproteins. J Endotoxin Res 2003;9:113-118. (Pubitemid 36603686)
69. Fujihara M, Muroi M, Tanamoto K, Suzuki T, Azuma H, Ikeda H. Molecular mechanisms of macrophage activation and deactivation by lipopolysaccharide: Roles of the receptor complex. Pharmacol Ther 2003;100:171-194. (Pubitemid 37377912)
70. Dobrovolskaia MA, Vogel SN. Toll receptors, CD14, and macrophage activation and deactivation by LPS. Microbes Infect 2002;4:903-914. (Pubitemid 34775232)
71. West MA, Heagy W. Endotoxin tolerance: A review. Crit Care Med 2002;30:S64-S73. (Pubitemid 34131164)
72. Baranova I, Vishnyakova T, Bocharov A, Chen Z, Remaley AT, Stonik J, Eggerman TL, Patterson AP. Lipopolysaccharide down regulates both scavenger receptor B1 and ATP binding cassette transporter A1 in RAW cells. Infect Immun 2002;70:2995-3003. (Pubitemid 34564159)
73. Buechler C, Ritter M, Quoc CD, Agildere A, Schmitz G. Lipopolysaccharide inhibits the expression of the scavenger receptor Cla-1 in human monocytes and macrophages. Biochem Biophys Res Commun 1999;262:251-254. (Pubitemid 29412655)
74. Khovidhunkit W, Moser AH, Shigenaga JK, Grunfeld C, Feingold KR. Endotoxin down-regulates ABCG5 and ABCG8 in mouse liver and ABCA1 and ABCG1 in J774 murine macrophages: Differential role of LXR. J Lipid Res 2003;44:1728-1736. (Pubitemid 37185884)
75. Linke RP, Bock V, Valet G, Rothe G. Inhibition of the oxidative burst response of N-formyl peptide-stimulated neutrophils by serum amyloid- A protein. Biochem Biophys Res Commun 1991;176:1100-1105.
76. Isersky C, Page DL, Cuatrecasas P, DeLellis RA, Glenner GG. Murine amyloidosis: Immunologic characterization of amyloid fibril protein. J Immunol 1971;107:1690-1698.
77. Linke RP, Sipe JD, Pollock PS, Ignaczak TF, Glenner GG. Isolation of a low-molecular-weight serum component antigenically related to an amyloid fibril protein of unknown origin. Proc Natl Acad Sci USA 1975;72:1473-1476.
78. Benditt EP, Hoffman JS, Eriksen N, Parmelee DC, Walsh KA. SAA, an apoprotein of HDL: Its structure and function. Ann N Y Acad Sci 1982;389:183-189. (Pubitemid 12013188)
79. Kisilevsky R, Benson MD, Axelrad MA, Boudreau L. The effect of a liver protein synthesis inhibitor on plasma SAA levels in a model of accelerated amyloid deposition. Lab Invest 1979;41:206-210. (Pubitemid 9257875)
80. Shirahama T, Skinner M, Cohen AS. Heterogeneous participation of the hepatocyte population in amyloid protein AA synthesis. Cell Biol Int Rep 1984;8:849-856.
81. Morrow JF, Stearman RS, Peltzman CG, Potter DA. Induction of hepatic synthesis of serum amyloid A protein and actin. Proc Natl Acad Sci USA 1981;78:4718-4722. (Pubitemid 12225551)
82. Sipe J. Revised nomenclature for serum amyloid A (SAA). Nomenclature Committee of the International Society of Amyloidosis. Part 2. Amyloid 1999;6:67-70.
83. Soler L, Luyten T, Stinckens A, Buys N, Cer? JJ, Niewold TA. Serum amyloid A3 (SAA3), not SAA1 appears to be the major acute phase SAA isoform in the pig. Vet Immunol Immunopathol 2011;141:109-115.
84. Ramadori G, Rieder H, Sipe J, Shirahama T, Meyer zum B?schenfelde KH. Murine tissue macrophages synthesize and secrete amyloid proteins different to amyloid A (AA). Eur J Clin Invest 1989;19:316-322. (Pubitemid 19184197)
85. Meek RL, Benditt EP. Rat tissues express serum amyloid A proteinrelated mRNAs. Proc Natl Acad Sci USA 1989;86:1890-1894. (Pubitemid 19087037)
86. de Beer MC, de Beer FC, Beach CM, Carreras I, Sipe JD. Mouse serum amyloid A protein. Complete amino acid sequence and mRNA analysis of a new isoform. Biochem J 1992;283 (Pt 3):673-678.
87. Yamada T, Miyake N, Itoh K, Igari J. Further characterization of serum amyloid A4 as a minor acute phase reactant and a possible nutritional marker. Clin Chem Lab Med 2001;39:7-10. (Pubitemid 32186271)
88. de Beer MC, de Beer FC, Gerardot CJ, Cecil DR, Webb NR, Goodson ML, Kindy MS. Structure of the mouse Saa4 gene and its linkage to the serum amyloid A gene family. Genomics 1996;34:139-142. (Pubitemid 26159886)
89. Cohen AS, Shirahama T, Sipe JD, Skinner M. Amyloid proteins, precursors, mediator, and enhancer. Lab Invest 1983;48:1-4. (Pubitemid 13110927)
90. Goldberger G, Bing DH, Sipe JD, Rits M, Colten HR. Transcriptional regulation of genes encoding the acute-phase proteins CRP, SAA, and C3. J Immunol 1987;138:3967-3971. (Pubitemid 17078281)
91. Selinger MJ, McAdam KP, Kaplan MM, Sipe JD, Vogel SN, Rosenstreich DL. Monokine-induced synthesis of serum amyloid A protein by hepatocytes. Nature 1980;285:498-500. (Pubitemid 10045068)
92. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-454. (Pubitemid 29084777)
93. Kushner I. The acute phase response: From Hippocrates to cytokine biology. Eur Cytokine Netw 1991;2:75-80.
94. Kushner I, Rzewnicki DL. The acute phase response: General aspects. In: Husby G. (ed). Clinical Rheumatology: Vol.8 No.3, Reactive Amyloidosis and the Acute Phase Response. London: Bailliere Tindall; 1994, pp. 513-530. (Pubitemid 24256889)
95. Lowell CA, Stearman RS, Morrow JF. Transcriptional regulation of serum amyloid A gene expression. J Biol Chem 1986;261:8453-8461. (Pubitemid 17202726)
96. Hoffman JS, Benditt EP. Plasma clearance kinetics of the amyloidrelated high density lipoprotein apoprotein, serum amyloid protein (apoSAA), in the mouse. Evidence for rapid apoSAA clearance. J Clin Invest 1983;71:926-934. (Pubitemid 13163265)
97. Tape C, Kisilevsky R. Apolipoprotein A-I and apolipoprotein SAA half-lives during acute inflammation and amyloidogenesis. Biochim Biophys Acta 1990;1043:295-300. (Pubitemid 20103665)
98. Kisilevsky R, Tam SP. Acute phase serum amyloid A, cholesterol metabolism, and cardiovascular disease. Pediatr Pathol Mol Med 2002;21:291-305. (Pubitemid 34619569)
99. Liang JS, Sipe JD. Recombinant human serum amyloid A (apoSAAp) binds cholesterol and modulates cholesterol flux. J Lipid Res 1995;36:37-46.
100. Liang JS, Schreiber BM, Salmona M, Phillip G, Gonnerman WA, de Beer FC, Sipe JD. Amino terminal region of acute phase, but not constitutive, serum amyloid A (apoSAA) specifically binds and transports cholesterol into aortic smooth muscle and HepG2 cells. J Lipid Res 1996;37:2109-2116. (Pubitemid 26357322)
101. Ohta S, Tanaka M, Sakakura K, Kawakami T, Aimoto S, Saito H. Defining lipid-binding regions of human serum amyloid A using its fragment peptides. Chem Phys Lipids 2009;162:62-68.
102. Benson MD, Aldo-Benson MA. SAA suppression of immune response in vitro: Evidence for an effect on T cell-macrophage interaction. J Immunol 1982;128:2390-2392. (Pubitemid 12124449)
103. Preciado-Patt L, Hershkoviz R, Fridkin M, Lider O. Serum amyloid A binds specific extracellular matrix glycoproteins and induces the adhesion of resting CD4+ T cells. J Immunol 1996;156:1189-1195. (Pubitemid 26048116)
104. Hershkoviz R, Preciado-Patt L, Lider O, Fridkin M, Dastych J, Metcalfe DD, Mekori YA. Extracellular matrix-anchored serum amyloid A preferentially induces mast cell adhesion. Am J Physiol 1997;273:C179-C187.
105. Xu L, Badolato R, Murphy WJ, Longo DL, Anver M, Hale S, Oppenheim JJ, Wang JM. A novel biologic function of serum amyloid A. Induction of T lymphocyte migration and adhesion. J Immunol 1995;155:1184-1190.
106. Zimlichman S, Danon A, Nathan I, Mozes G, Shainkin-Kestenbaum R. Serum amyloid A, an acute phase protein, inhibits platelet activation. J Lab Clin Med 1990;116:180-186. (Pubitemid 20269811)
107. Pruzanski W, de Beer FC, de Beer MC, Stefanski E, Vadas P. Serum amyloid A protein enhances the activity of secretory non-pancreatic phospholipase A2. Biochem J 1995;309 (Pt 2):461-464.
108. Tietge UJ, Maugeais C, Lund-Katz S, Grass D, deBeer FC, Rader DJ. Human secretory phospholipase A2 mediates decreased plasma levels of HDL cholesterol and apoA-I in response to inflammation in human apoA-I transgenic mice. Arterioscler Thromb Vasc Biol 2002;22:1213-1218. (Pubitemid 34764876)
109. Mitchell TI, Coon CI, Brinckerhoff CE. Serum amyloid A (SAA3) produced by rabbit synovial fibroblasts treated with phorbol esters or interleukin 1 induces synthesis of collagenase and is neutralized with specific antiserum. J Clin Invest 1991;87:1177-1185.
110. Manley PN, Ancsin JB, Kisilevsky R. Rapid recycling of cholesterol: The joint biologic role of C-reactive protein and serum amyloid A. Med Hypotheses 2006;66:784-792. (Pubitemid 43181624)
111. Skubitz KM. Neutrophilic Leukocytes. In: Greer JP, Foerster J, Lukens JN, Rodgers GM, Paraskevas F, Glader B. (eds). Wintrobes Clinical hematology. Philadelphia: Lippincott Williams & Wilkins; 2004, pp. 268-310.
112. Weinberg JB. Mononuclear Phagocytes. In: Greer JP, Foerster J, Lukens JN, Rodgers GM, Paraskevas F, Glader B. (eds). Wintrobes Clinical hematology. Philadelphia: Lippincott Williams & Wilkins; 2004, pp. 350-386.
113. Tam SP, Kisilevsky R, Ancsin JB. Acute-phase-HDL remodeling by heparan sulfate generates a novel lipoprotein with exceptional cholesterol efflux activity from macrophages. PLoS ONE 2008;3:e3867.
114. Tam SP, Kisilevsky R. The influence of serum amyloid A on ATP binding cassette A1 and G1 mRNA levels in cholesterol laden macrophages. Amyloid 2010;17 Suppl 1:108.
115. de Beer MC, Ji A, Jahangiri A, Vaughan AM, de Beer FC, van der Westhuyzen DR, Webb NR. ATP binding cassette G1-dependent cholesterol efflux during inflammation. J Lipid Res 2011;52:345-353.
116. Dikopoulos N, Schmid RM, Bachem M, Buttenschoen K, Adler G, Chiang JY, Weidenbach H. Bile synthesis in rat models of inflammatory bowel diseases. Eur J Clin Invest 2007;37:222-230.
117. Roberts MS, Liu X, Zou Y, Siebert GA, Chang P, Whitehouse MW, Fletcher L, Crawford DH. Effect of adjuvant-induced systemic inflammation in rats on hepatic disposition kinetics of taurocholate. Am J Physiol Gastrointest Liver Physiol 2011;300:G130-G136.
118. Feingold KR, Grunfeld C. The acute phase response inhibits reverse cholesterol transport. J Lipid Res 2010;51:682-684.
119. Davis RA, Miyake JH, Hui TY, Spann NJ. Regulation of cholesterol- 7?-hydroxylase: BAREly missing a SHP. J Lipid Res 2002;43:533-543. (Pubitemid 34252327)
120. Woollett LA. Origin of cholesterol in the fetal golden Syrian hamster: Contribution of de novo sterol synthesis and maternal-derived lipoprotein cholesterol. J Lipid Res 1996;37:1246-1257. (Pubitemid 26239079)
121. Ding ST, Lilburn MS. The developmental expression of acyl-coenzyme A:cholesterol acyltransferase in the yolk sac membrane, liver, and intestine of developing embryos and posthatch turkeys. Poult Sci 2000;79:1460-1464.
122. Hayden Lichtenberg M, Wilke CS, McConihay JA, Granholm NA, Woollett LA. Yolk sac cholesteryl ester secretion rates can be manipulated in the Golden Syrian hamster: Effect of yolk sac cholesterol concentrations. Biochim Biophys Acta 2005;1735:214-221. (Pubitemid 41140431)
123. Shand JH, West DW, McCartney RJ, Noble RC, Speake BK. The esterification of cholesterol in the yolk sac membrane of the chick embryo. Lipids 1993;28:621-625. (Pubitemid 23207095)
124. Kelly KJ, Kluve-Beckerman B, Dominguez JH. Acute-phase response protein serum amyloid A stimulates renal tubule formation: Studies in vitro and in vivo. Am J Physiol Renal Physiol 2009;296:F1355-F1363.
125. Kelly KJ, Kluve-Beckerman B, Zhang J, Dominguez JH. Intravenous cell therapy for acute renal failure with serum amyloid A protein-reprogrammed cells. Am J Physiol Renal Physiol 2010;299:F453-F464.
126. Batetta B, Mulas MF, Sanna F, Putzolu M, Bonatesta RR, Gasperi- Campani A, Roncuzzi L, et al. Role of cholesterol ester pathway in the control of cell cycle in human aortic smooth muscle cells. FASEB J 2003;17:746-748.
127. Dessi S, Batteta B. Intracellular cholesterol homeostasis: Old and new players. In: Pani A, Dessi S. (eds). Cell Growth and Cholesterol Esters. New York, New York: Kluwer Academic/Plenum Publishers; 2004, pp. 1-12.
128. Meek RL, Hoffman JS, Benditt EP. Amyloidogenesis. One serum amyloid A isotype is selectively removed from the circulation. J Exp Med 1986;163:499-510. (Pubitemid 16141956)
129. Hoffman JS, Ericsson LH, Eriksen N, Walsh KA, Benditt EP. Murine tissue amyloid protein AA. NH2-terminal sequence identity with only one of two serum amyloid protein (ApoSAA) gene products. J Exp Med 1984;159:641-646. (Pubitemid 14194003)
130. Tape C, Tan R, Nesheim M, Kisilevsky R. Direct evidence for circulating apoSAA as the precursor of tissue AA amyloid deposits. Scand J Immunol 1988;28:317-324. (Pubitemid 18263218)
131. Husebekk A, Skogen B, Husby G, Marhaug G. Transformation of amyloid precursor SAA to protein AA and incorporation in amyloid fibrils in vivo. Scand J Immunol 1985;21:283-287. (Pubitemid 15108055)
132. Westlake SL, Colebatch AN, Baird J, Curzen N, Kiely P, Quinn M, Choy E, et al. Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: A systematic literature review. Rheumatology (Oxford) 2011;50:518-531.
133. Pieringer H, Pichler M. Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: Vascular alterations and possible clinical implications. QJM 2011;104:13-26.
134. Barnabe C, Martin BJ, Ghali WA. Systematic review and meta-analysis: Anti-tumor necrosis factor a therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2011;63:522-529.
135. Meune C, Touz?E, Trinquart L, Allanore Y. High risk of clinical cardiovascular events in rheumatoid arthritis: Levels of associations of myocardial infarction and stroke through a systematic review and meta-analysis. Arch Cardiovasc Dis 2010;103:253-261.
136. Rho YH, Chung CP, Oeser A, Solus J, Asanuma Y, Sokka T, Pincus T, et al. Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis. Arthritis Rheum 2009;61:1580-1585.
137. Gotlieb AI, Benditt EP, Schwartz SM. Blood Vessels. In: Rubin E, Farber JL. (eds). Pathology. Philadelphia, New York: Lippincott- Raven; 1999, pp. 481-530.
138. Vanlente F. Markers of inflammation as predictors in cardiovascular disease. Clin Chim Acta 2000;293:31-52.
139. Delanghe JR, Langlois MR, De Bacquer D, Mak R, Capel P, Van Renterghem L, De Backer G. Discriminative value of serum amyloid A and other acute-phase proteins for coronary heart disease. Atherosclerosis 2002;160:471-476. (Pubitemid 34159343)
140. Liuzzo G, Baisucci LM, Gallimore JR, Caligiuri G, Buffon A, Rebuzzi AG, Pepys MB, Maseri A. Enhanced inflammatory response in patients with preinfarction unstable angina. J Am Coll Cardiol 1999;34:1696-1703.
141. Navab M, Reddy S, Van Lenten BJ, Anantharamaiah GM, Fogelman AM. Role of dysfunctional HDL in atherosclerosis. J Lipid Res 2008;50 Suppl 1:145-149.
142. Luchtefeld M, Schunkert H, Stoll M, Selle T, Lorier R, Grote K, Sagebiel C, et al. Signal transducer of inflammation gp130 modulates atherosclerosis in mice and man. J Exp Med 2007;204:1935-1944. (Pubitemid 47236328)
143. Danesh J, Pepys MB. C-reactive protein and coronary disease: Is there a causal link? Circulation 2009;120:2036-2039.
144. Mishra VK, Palgunachari MN, Lund-Katz S, Phillips MC, Segrest JP, Anantharamaiah GM. Effect of the arrangement of tandem repeating units of class A amphipathic ?-helixes on lipid interaction. J Biol Chem 1995;270:1602-1611.